Search

Jan Jozef Scicinski

from Sunnyvale, CA
Age ~59
Get Report
Also known as:
Jan J Scicinski, Jan B Scicinski, Jan J Scicinska, Jan H Scicinska, Jan J Scicinsk, Jan H Scicinsk, Anna Scicinsk
Phone and address:
928 Mackenzie Dr, Sunnyvale, CA 94087
Related to:
Anna Scicinska, 58
Connected to:
Marissa L Scicluna, 36Stacey E Scicluna, 58Carol J Scicutella, 67Larry S Scidurlo, 63Joanne C Scielzo, 43Jennifer D Science, 58Laura A Sciepura, 55Evette M Scierka, 48Cheryl A Scieszinski, 78Ann M Scifo, 68

Jan Scicinski Phones & Addresses

  • 928 Mackenzie Dr, Sunnyvale, CA 94087
  • 7507 Wellesley Park S, Raleigh, NC 27615 (408) 777-8477
  • Saratoga, CA
  • 2504 Duck Pond Cir, Morrisville, NC 27560
  • Mountain View, CA
  • Santa Clara, CA

Work

Company: Radiorx, inc 2009 Position: Vp, research and development

Education

Degree: Ph.D School / High School: University of Cambridge 1999 to 2001 Specialities: Chemistry

Skills

Drug Development • Medicinal Chemistry • Pharmaceutical Industry • Drug Discovery • Drug Delivery • Biotechnology • R&D • Clinical Development • Technology Transfer • Life Sciences • Chemistry • Organic Chemistry • Fda • Biopharmaceuticals • Organic Synthesis • Glp • Oncology • Formulation • Purification • Protein Chemistry • Hplc • Chromatography • Lifesciences • Cell • Analytical Chemistry • Clinical Trials • Molecular Biology • Cro • Mass Spectrometry • Lc Ms • High Throughput Screening • Regulatory Affairs • Proteomics • Pharmaceutics • Gmp • Validation • Sop • Regulatory Submissions • Commercialization • Biochemistry • Immunology • Immunoassays • In Vitro • Ind • Nmr • Cancer • Pharmacology • Research and Development

Languages

Polish

Ranks

Certificate: Fellow, Royal Society of Chemistry. Chartered Chemist. (Cchem, Frsc)

Industries

Pharmaceuticals

Resumes

Resumes

Jan Scicinski Photo 1

Founder President And Chief Executive Officer

View page
Location:
San Francisco, CA
Industry:
Pharmaceuticals
Work:
RadioRx, Inc since 2009
VP, Research and Development
DURECT Corporation 2006 - 2009
Director, New Product Opportunity Assessment
ALZA Corporation 2004 - 2006
Assoc Dir/Principal Scientist
Nuada Pharmaceuticals / ChemCodes Inc 2002 - 2004
Senior Director Medicinal Chemistry and Chemical Technology
GlaxoSmithKline 1986 - 2002
Senior Research Chemist
Education:
University of Cambridge 1999 - 2001
Ph.D, Chemistry Imperial College London 1983 - 1986
BSc, Chemistry
Skills:
Drug Development
Medicinal Chemistry
Pharmaceutical Industry
Drug Discovery
Drug Delivery
Biotechnology
R&D
Clinical Development
Technology Transfer
Life Sciences
Chemistry
Organic Chemistry
Fda
Biopharmaceuticals
Organic Synthesis
Glp
Oncology
Formulation
Purification
Protein Chemistry
Hplc
Chromatography
Lifesciences
Cell
Analytical Chemistry
Clinical Trials
Molecular Biology
Cro
Mass Spectrometry
Lc Ms
High Throughput Screening
Regulatory Affairs
Proteomics
Pharmaceutics
Gmp
Validation
Sop
Regulatory Submissions
Commercialization
Biochemistry
Immunology
Immunoassays
In Vitro
Ind
Nmr
Cancer
Pharmacology
Research and Development
Languages:
Polish
Certifications:
Fellow, Royal Society of Chemistry. Chartered Chemist. (Cchem, Frsc)

Publications

Us Patents

Peptidase Inhibitors

View page
US Patent:
20080234292, Sep 25, 2008
Filed:
Jul 21, 2005
Appl. No.:
11/571857
Inventors:
Susan Marie Royalty - Cary NC, US
James Ford Burns - Glen Ridge NJ, US
Jan Jozef Scicinski - Sunnyvale CA, US
Robert James Foglesong - Durham NC, US
Kellee Griffin Ring - Garner NC, US
Tatyana Dyakonov - Durham NC, US
David Middlemiss - Hertforshire, GB
International Classification:
A61K 31/40
C07D 207/16
C07D 401/12
C07D 403/12
C07D 413/12
C07D 277/04
A61K 31/497
A61K 31/506
A61K 31/4439
A61K 31/426
A61K 31/422
A61P 3/10
US Classification:
51425505, 548540, 5462791, 544294, 544405, 548243, 548200, 514275, 514343, 514365, 514380, 514423
Abstract:
The present invention relates to a series of novel compounds having the formula (I) wherein: X is NRor O; n is 1 or 2; A is a bicyclic carbocycle and R1 and R2 are as described herein. The compounds are useful as DPP-IV inhibitors, such as for the treatment of diabetes.

Compounds And Methods Of Use Thereof

View page
US Patent:
20080319044, Dec 25, 2008
Filed:
Oct 27, 2005
Appl. No.:
11/718286
Inventors:
John R. Didsbury - Raleigh NC, US
Tatyana A. Dyakonov - Durham NC, US
Simon N. Haydar - Newton PA, US
Michael L. Jones - Chapel Hill NC, US
Francine F. Li - Chester Springs PA, US
Christopher J. Markworth - Durham NC, US
Jessymol Mathew - Raleigh NC, US
Frank J. Schoenen - Lawrence KS, US
Jan J. Scicinski - Sunnyvale CA, US
David Middlemiss - Bishop's Stortford, GB
Assignee:
NUADA, LLC - Durham NC
International Classification:
A61K 31/404
C07D 209/04
A61P 1/00
A61P 19/02
A61P 17/06
A61P 25/28
A61P 9/00
A61P 3/10
A61P 35/00
A61P 9/12
A61P 15/10
US Classification:
514415, 548491
Abstract:
Indole boronic acid compounds, and analogs thereof, and pharmaceutical formulations are described, along with methods of use thereof for inhibiting inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) in a subject in need thereof.

Indole, Benzimidazole, And Benzolactam Boronic Acid Compounds, Analogs Thereof And Methods Of Use Thereof

View page
US Patent:
20090264384, Oct 22, 2009
Filed:
Nov 10, 2008
Appl. No.:
12/268237
Inventors:
John R. Didsbury - Raleigh NC, US
Tatyana Dyakonov - Greensboro NC, US
Simon N. Haydar - Newton PA, US
Michael L. Jones - Chapel Hill NC, US
Francine F. Li - Chester Springs PA, US
Christopher J. Markworth - Durham NC, US
Jessy Matthew - Raleigh NC, US
Frank J. Schoenen - Laurence KS, US
Jan J. Scicinski - Mountain View CA, US
David Middlemiss - Bishop's Stortford, GB
James F. Burns - Glen Ridge NJ, US
Leonard A. Cabana - Durham NC, US
Glenn C. Collupy - Durham NC, US
David N. Vanvliet - Chapel Hill NC, US
Assignee:
Nuada, Inc. - Durham NC
International Classification:
A61K 31/69
A61P 1/00
A61P 19/02
A61P 17/06
A61P 11/06
A61P 11/00
A61P 17/00
A61P 37/08
US Classification:
514 64
Abstract:
Benzimidazole, indole and benzolactam boronic acid compounds, analogs thereof, and pharmaceutical formulations are described, along with methods of use thereof for inhibiting inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) in a subject in need thereof.

Oral Pharmaceutical Dosage Forms

View page
US Patent:
20100260844, Oct 14, 2010
Filed:
Nov 3, 2009
Appl. No.:
12/590195
Inventors:
Jan J. Scicinski - Sunnyvale CA, US
William W. van Osdol - Mountain View CA, US
Michael H. Arenberg - Campbell CA, US
Jaymin Shah - Sunnyvale CA, US
International Classification:
A61K 31/445
A61K 9/00
A61P 25/00
US Classification:
424484, 514317
Abstract:
Controlled release oral dosage forms suitable for administration of methylphenidate are provided. Abuse-resistant controlled release oral dosage forms suitable for administration of methylphenidate are also provided. Methods of treating ADD and ADHD using the oral dosage forms are also provided.

Organonitro Compounds For Use In Treating Non-Hodgkin's Lymphoma And Leukemia, And Methods Relating Thereto

View page
US Patent:
20120149678, Jun 14, 2012
Filed:
Dec 9, 2011
Appl. No.:
13/315888
Inventors:
Bryan T. Oronsky - Los Altos Hills CA, US
Susan Knox - Stanford CA, US
Jan Scicinski - Saratoga CA, US
Shoucheng Ning - Santa Clara CA, US
International Classification:
A61K 31/397
A61K 31/4468
A61K 31/12
A61K 31/16
A61K 31/04
A61P 35/02
A61K 31/445
A61K 31/255
A61K 31/22
A61K 31/40
A61P 35/00
US Classification:
51421017, 514423, 514315, 514676, 51421001, 514426, 514628, 514517, 514518, 514550, 514742, 514740
Abstract:
The invention provides organonitro compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat non-Hodgkin's lymphoma and certain leukemias in a patient. The compounds, compositions, kits, and methods are contemplated to provide a therapeutic benefit in treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, and acute lymphoblastic leukemia. Exemplary organonitro compounds described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.

Acyclic Organonitro Compounds For Use In Treating Cancer

View page
US Patent:
20130053418, Feb 28, 2013
Filed:
Aug 24, 2012
Appl. No.:
13/593737
Inventors:
Jan Scicinski - Saratoga CA, US
Bryan T. Oronsky - Los Altos Hills CA, US
Robert Wardle - Logan UT, US
Louis Cannizzo - Ogden UT, US
Nicholas A. Straessler - North Salt Lake UT, US
International Classification:
A61K 31/08
A61K 31/27
A61K 31/17
A61K 31/16
A61K 31/18
C07D 401/12
A61K 31/225
A61K 31/444
A61P 35/00
C07C 205/29
C07C 205/49
A61K 31/265
A61K 31/22
US Classification:
514332, 514716, 514512, 514478, 514484, 514489, 514588, 514626, 514601, 514551, 514547, 514531, 568589, 558276, 546326
Abstract:
The present invention provides acyclic, geminal-dinitro organic compounds, methods of synthesizing the compounds, pharmaceutical compositions, therapeutic methods, and medical kits for treating various conditions using such compounds and pharmaceutical compositions. The compounds and compositions are useful in the treatment of cancer.

Treatment Of Gliomas Using Organonitro Compound Combination Therapy

View page
US Patent:
20200375982, Dec 3, 2020
Filed:
Dec 12, 2019
Appl. No.:
16/712148
Inventors:
- La Jolla CA, US
Jan Scicinski - Saratoga CA, US
International Classification:
A61K 31/495
A61K 31/397
A61K 9/00
A61K 31/4745
Abstract:
The invention provides therapeutic methods and kits for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab.

Sulfoxyalkyl Organonitro And Related Compounds And Pharmaceutical Compounds For Use In Medicine

View page
US Patent:
20200157047, May 21, 2020
Filed:
Oct 13, 2017
Appl. No.:
16/341538
Inventors:
- La Jolla CA, US
Jan Scicinski - Saratoga CA, US
International Classification:
C07D 205/04
Abstract:
The invention provides sulfoxyalkyl organonitro and related compounds, compositions containing such compounds, and methods for using such compounds and compositions to treat medical disorders, such as a neurodegenerative disorder, autoimmune disease, infection, or cancer in a patient. Exemplary sulfoxyalkyl organonitro compounds described herein include ((2-(3,3-dinitroaze-tidin-1-yl)-2-oxoethyl)sulfinyl)-D-alanine and variants thereof.
Control profile
Jan Jozef Scicinski from Sunnyvale, CA, age ~59 Get Report